Government ❯ Regulatory Agencies ❯ FDA

Drug Approval Process

Mifepristone Compounding Regulations Mifepristone Review Clinical Trials Public Health Medication Safety Over-the-Counter Drugs Mifepristone Regulation Biologics License Application MDMA for PTSD

Atara Biotherapeutics Hit With Investor Class Action Over FDA Setbacks

Shareholders seek recovery after alleged misstatements about tabelecleucel’s approval path.

Plaintiff Firms Step Up uniQure Solicitation After FDA Rebuke, With April 13 Lead-Plaintiff Deadline

Hawley Seeks to Revoke FDA Approval of Abortion Pill Mifepristone With New Senate Bill

FDA Demands Placebo-Controlled Trial for UniQure’s Huntington’s Gene Therapy

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Strive Compounding Sues Lilly and Novo, Alleging Antitrust Push to Block Compounded GLP-1s

Louisiana Joins Texas, Florida in New Court Moves Targeting FDA Abortion Pill Rules

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

FDA Proposes Adding Bemotrizinol to U.S. Sunscreens, Invites Public Comment

Novo Nordisk Presses India Expansion and Higher-Dose Push as Analyst Views Diverge

Texas and Florida Sue FDA to Overturn Mifepristone Approvals and Mail-Order Access

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

ACLU Sues FDA to Obtain Records on Mifepristone Review

Cytokinetics Investors Face Nov. 17 Deadline to Seek Lead Role in Aficamten Securities Case

Intellia Pauses Phase 3 Trials of CRISPR Therapy After Severe Liver Event

Kenvue Asks FDA to Reject Autism Warning on Tylenol in Pregnancy

ATyr’s Sarcoidosis Drug Fails Phase 3 Goal, Shares Plunge Over 80%

FDA Creates 'Green List' for GLP-1 Ingredients as WHO Names the Drugs Essential

Kennedy Alleges Biden Team Skewed Abortion-Pill Data as FDA Review of Mifepristone Proceeds

FDA Warns Five Brands Over Unauthorized Mousse Sunscreens